Loading...
XSTO
ACTI
Market cap35mUSD
May 28, Last price  
0.28SEK
1D
3.36%
1Q
203.40%
Jan 2017
-96.47%
Name

Active Biotech AB publ

Chart & Performance

D1W1MN
XSTO:ACTI chart
No data to show
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
15.96%
Rev. gr., 5y
-11.87%
Revenues
0k
9,152,00066,359,00012,077,00053,456,00010,772,00011,356,000234,593,000219,092,000108,145,0002,265,00016,275,00019,042,00020,246,00020,051,0008,425,0006,725,0000000
Net income
-39m
L-13.97%
-135,415,000-139,180,000-207,718,000-181,586,000-223,977,000-221,065,000-94,550,000-175,015,000-212,086,000-231,512,000-193,531,000-59,584,000-108,793,000-36,878,000-36,066,000-32,117,000-49,883,000-58,691,000-45,800,000-39,400,000
CFO
-40m
L-11.68%
-192,510,000-100,133,000-186,704,000-159,463,000-224,772,000-196,320,000-46,971,000-240,396,000-102,250,000-267,090,000-217,887,000-73,163,000-46,447,000-40,647,000-35,813,000-32,216,000-46,166,000-54,850,000-45,741,000-40,400,000
Earnings
Aug 20, 2025

Profile

Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.
URL
https://www.activebiotech.com/
IPO date
Dec 01, 1986
Employees
8
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
39,900
48,159
59,380
Unusual Expense (Income)
NOPBT
(39,900)
(48,159)
(59,380)
NOPBT Margin
Operating Taxes
319
Tax Rate
NOPAT
(39,900)
(48,159)
(59,699)
Net income
(39,400)
-13.97%
(45,800)
-21.96%
(58,691)
17.66%
Dividends
Dividend yield
Proceeds from repurchase of equity
33,200
43,468
46,832
BB yield
-72.58%
-35.07%
-18.72%
Debt
Debt current
1,545
1,606
Long-term debt
7,545
10,470
Deferred revenue
Other long-term liabilities
2,230
Net debt
(27,400)
(27,128)
(30,096)
Cash flow
Cash from operating activities
(40,400)
(45,741)
(54,850)
CAPEX
(245)
Cash from investing activities
(245)
Cash from financing activities
31,600
40,163
43,757
FCF
(41,484)
(46,611)
(65,018)
Balance
Cash
27,400
36,218
41,796
Long term investments
376
Excess cash
27,400
36,218
42,172
Stockholders' equity
(3,441,490)
(3,396,361)
Invested Capital
34,300
3,476,702
3,436,674
ROIC
ROCE
EV
Common stock shares outstanding
420,431
271,524
260,038
Price
0.11
-76.17%
0.46
-52.55%
0.96
-23.89%
Market cap
45,743
-63.10%
123,951
-50.45%
250,156
-19.44%
EV
18,343
96,823
220,060
EBITDA
(39,900)
(46,484)
(57,885)
EV/EBITDA
Interest
206
Interest/NOPBT